Emerging Companies

 John Carroll, editor of Fierce Biotech, shares what he won't miss at the 2011 BIO International Convention.

As Japan works to stabilize the crippled nuclear power plant in Fukushima, people are stocking up on potassium iodide tablets – one of the only drugs available to block the body's absorption of some radioactive materials.

Partnering decisions can make or break a company’s value. Pursuing the right partnership deal can ultimately increase a company’s value but conversely, the wrong decision can ultimately kill a company’ value.

Upward trends and investment opportunities will be focus of BIO’s World Congress in May.

The Massachusetts Life Sciences Center, which is tasked with administering the $1 billion state's life sciences initiative, has awarded five loans to start up companies, totaling $3.75 million.

Budget victories will help biotechnology in the Commonwealth

The Patent Reform Act of 2011 would strengthen and improve our nation’s patent system, spurring innovation and job creation.

This month, BIO is leading a delegation of biopharma CEOs to China for meetings with members of the Chinese biotech community and government leaders. The mission illustrates a strong commitment on behalf of the western biotechnology industry to encourage China to strengthen its support for biotech innovation and take steps to enhance greater investment and collaboration with companies in China. The series of meetings between China’s local industry and government leaders and biotech CEOs will lay the foundation for increased cooperation to help biotech flourish in China.

Industry leaders point out that biotech-enabled advanced biofuels spur job growth and reduce U.S. dependence on imported oil.

Dr. Ferstenberg discusses an innovative program to guide small emerging biotech companies and how women in biotech can accelerate their leadership within the industry.

Dr. Ferstenberg discusses an innovative program to guide small emerging biotech companies and how women in biotech can accelerate their leadership within the industry. 

New listing requirements for proposed market would give more biotech companies option of going public.

Letters, Testimony & Comments

April 30 2015
On behalf of the Biotechnology Industry Organization Before the United States House of Representatives Committee on Financial Services, Subcommittee on Capital Markets and Government Sponsored Enterprises --- Legislative Proposals to Enhance Capital Formation and Reduce Regulatory Burdens
April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.

Press Releases

April 29 2016
Bill would enhance the voice of emerging companies at the SEC Washington, D.C. (April 29, 2016) – Today, the Biotechnology Innovation Organization (BIO) applauds Senators Heidi Heitkamp (D-ND), Dean Heller (R-NV) and Gary Peters (D-MI) for introducing the SEC Small Business Advocate Act, which would ensure that growing companies have a strong, independent voice at the Securities and Exchange Commission (SEC). 
February 9 2016
Elements of the President’s budget proposal for 2017 directly threaten his Administration’s goal of curing cancer through advances in precision medicine
February 2 2016
BIO applauds the House of Representatives for approving the SEC Small Business Advocate Act (H.R. 3784) and the Small Business Capital Formation Enhancement Act (H.R. 4168). These bills would enhance the role that small businesses play in the decision-making process at the Securities and Exchange Commission, ensuring that SEC policies support the growth of emerging biotech innovators.
December 16 2015
BIO today welcomed legislation to extend critical tax incentives that are important to biotechnology companies. The legislation would make permanent the important Research & Development Tax Credit.
December 2 2015
BIO supports legislation to follow up on the success of the JOBS Act